Release Date: November 16, 2015
Expiration Date: November 16, 2016
Community Practice Connections™: Current and Emerging Strategies in the Management of Early Breast Cancer, is a series of short video interviews with Drs. O’Shaughnessy, Jahanzeb, and Holmes, who address a variety of questions commonly faced by practicing community oncologists. This online activity serves as an update on advances in the management of early-stage breast cancer, with a focus on the clinical implications of novel therapies, recent clinical trial data, and the management of predictable adverse events in patients with HER2-positive disease.
New management and treatment strategies with current and emerging compounds in the adjuvant setting continue to change treatment paradigms in this therapeutic space. This activity provides a unique opportunity for medical, surgical, and radiation oncologists and other healthcare professionals to learn from these experts in breast cancer in order to maintain state-of-the-art knowledge about the wide variety of advances in breast cancer treatment and management, with the goal of maximizing patient outcomes.
CME Activity Table of Contents
- Treatment Selection
- New Adjuvant Trial Data
- HER2-Targeted Therapy: Adverse Events
- Neoadjuvant Therapy: Minimizing Missed Opportunities
- Unmet Clinical Needs
Instructions For This Activity & Receiving Credit
This educational activity is directed toward medical, surgical, and radiation oncologists interested in the treatment of patients with breast cancer. Fellows, nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other healthcare professionals interested in the treatment of breast cancer may also participate.
Educational ObjectivesAt the conclusion of this activity, you should be better prepared to:
- Discuss contemporary adjuvant treatment strategies for patients with HER2-overexpressing breast cancer in the context of efficacy and areas of remaining unmet clinical need
- Assess recent clinical data concerning the effectiveness of emerging strategies for the treatment of early HER2-positive breast cancer
- Explain methods to proactively mitigate predictable treatment-related adverse events in patients with HER2-positive breast cancer
- Apply clinical trial evidence to the management of patients with early-stage HER2-positive breast cancer
Faculty, Staff, and Planners' DisclosuresFaculty
Joyce A. O'Shaughnessy, MD
Co-Director, Breast Cancer Research
Baylor Charles A. Sammons Cancer Center
The US Oncology Network
Frankie Ann Holmes, MD, FACP
Associate Director, Breast Oncology Research
Mohammad Jahanzeb, MD
Professor of Clinical Medicine, Medical Director, Associate Center Director for Community Outreach
University of Miami Health System
The following individuals have no relevant financial relationships with commercial interests:
Frankie Ann Holmes, MD, FACP
The staff of PER®
The following individuals have relevant financial relationships with commercial interests to disclose:
Mohammad Jahanzeb, MD, FACP – Research Support: Lilly, AbbVie, Genentech, Novartis; Consultant: Novartis; Joyce O'Shaughnessy, MD – Consultant: Arno Therapeutics, AstraZeneca, Celgene, Corcept, Eisai, Genentech, GlaxoSmithKline, Lilly, J&J, Merrimack Pharmaceuticals, Novartis, Pfizer, Roche, Sanofi, Takeda Pharmaceutical, MedFusion
Accreditation/Designation of Credit Statement
Physicians' Education Resource®, LLC, (PER®) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
PER® designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Acknowledgment of Commercial Support
This activity is supported by an educational grant from Puma Biotechnology, Inc.
Disclosure Policy and Resolution of Conflicts of Interest (COI)
It is the policy of PER® to ensure the fair balance, independence, objectivity, and scientific objectivity in all of our CME activities. In accordance with ACCME guidelines, PER® requires everyone who is in a position to control the content of an educational activity, including spouses/partners, to disclose all relevant financial relationships with any commercial interest to participants as part of the activity planning process. PER® has implemented mechanisms to identify and resolve all conflicts of interest prior to release of this activity.
Off-Label Disclosure and Disclaimer
This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only, and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options for a specific patient's medical condition.
The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any of the companies that provided commercial support for this activity.
Hardware And Software Requirements
Internet Explorer v.7 or greater (for Windows) | Mozilla Firefox v.2 or greater (for Windows, Mac, Linux)
Minimum System Requirements (Windows)
- A Pentium-based PC or compatible computer
- At least 64MB of RAM
- Windows 95/98/NT/ME/2000/XP/Vista system software
- Screen resolution of 1024 x 786 or larger recommended
- PDF Reader: Adobe Reader 5.0 or higher, Foxit Reader 2.0 or likewise